What the FDA labels say about taking them together
Buprenorphine and gabapentin
Buprenorphine's FDA label (Brixadi) of December 31, 2025 names gabapentin in its drug interactions section, and gabapentin's label names buprenorphine too. The buprenorphine label: “Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death.”
Check it at the source: the buprenorphine FDA label on DailyMed (effective June 5, 2026); the gabapentin FDA label on DailyMed (effective May 12, 2026, Viatris Specialty LLC).
What does the buprenorphine label say about gabapentin?
Brixadi label (Braeburn Inc., December 31, 2025), drug interactionsBenzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. … sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), and other opioids.
Brixadi label (Braeburn Inc., December 31, 2025), warnings and precautionsUse of Benzodiazepines or Other CNS Depressants Concomitant use of buprenorphine and benzodiazepines and/or other CNS depressants (e.g., alcohol, non-benzodiazepine sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin or pregabalin], and other opioids) increases the risk of adverse reactions including overdose, respiratory depression, and death.
Butrans label (Knoa Pharma LLC, May 1, 2026), drug interactionsBenzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. … sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol.
Butrans label (Knoa Pharma LLC, May 1, 2026), warnings and precautionsRisks from Concomitant Use with Benzodiazepines or Other CNS Depressants Profound sedation, respiratory depression, coma, and death may result from the concomitant use of BUTRANS with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin and pregabalin], and other opioids).
Source: FDA drug label (Brixadi, NDA210136), Braeburn Inc., effective December 31, 2025 (SPL set 5d8a8fd0-8619-422a-a664-d1d2e8970f48), via openFDA
Source: FDA drug label (Butrans, NDA021306), Knoa Pharma LLC, effective May 1, 2026 (SPL set 794aa355-66de-41b8-aedf-f2c40f6bc664), via openFDA
Source: FDA drug label (Buprenorphine HCl), SpecGx LLC, effective June 5, 2026 (SPL set b60d514d-a88a-4fa2-a5b0-30ac29e04973), via openFDA; the full label on DailyMed
What does the gabapentin label say about buprenorphine?
Gabapentin label, drug interactionsRespiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e.g., morphine, hydrocodone, oxycodone, buprenorphine) [see Warnings and Precautions (5.8) ].
Source: FDA drug label (Neurontin), Viatris Specialty LLC, effective May 12, 2026 (SPL set 97935fd9-1d4a-43b6-a5d9-de994591187b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Buprenorphine | Gabapentin | |
|---|---|---|
| Labeled for | Opioid use disorder, Pain | Nerve pain and fibromyalgia, Seizures and epilepsy |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.277 per tablet 2 mg tablet sl | $0.0218 per capsule 100 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once